|1.||Lode, Holger N: 7 articles (05/2014 - 07/2005)|
|2.||Yu, Alice L: 5 articles (01/2014 - 01/2009)|
|3.||Sondel, Paul M: 4 articles (05/2014 - 07/2006)|
|4.||Handgretinger, Rupert: 4 articles (05/2014 - 09/2004)|
|5.||Berthold, Frank: 4 articles (01/2011 - 04/2002)|
|6.||Hero, Barbara: 4 articles (01/2011 - 04/2002)|
|7.||Gillies, Stephen D: 3 articles (05/2014 - 10/2007)|
|8.||Gan, Jacek: 3 articles (05/2014 - 07/2006)|
|9.||Hank, Jacquelyn A: 3 articles (05/2014 - 07/2006)|
|10.||Eger, Christin: 3 articles (05/2014 - 12/2013)|
07/01/2005 - "In order to improve the outcome, passive immunotherapy using human-mouse chimeric monoclonal anti-disialoganglioside GD2 antibody ch14.18 has been evaluated in early phase clinical trials with promising results in progressing stage 4 neuroblastoma patients. "
04/15/2013 - "Survival of NOD/SCID mice bearing disseminated neuroblastoma improved when treated with thawed and immediately intravenously infused cryopreserved aNK cells compared with untreated mice and was further improved when ch14.18 was added. "
07/01/2005 - "Third, the efficacy of ch14.18/CHO was evaluated in the NXS2 neuroblastoma model in vivo. "
09/01/2013 - "Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study."
02/01/2005 - "The monoclonal anti-GD2 antibody 14.18 is widely used for diagnostic purposes in neuroblastoma, and in its mouse/human chimeric form (ch14.18) now enters passive immunotherapeutic regimens in phase II clinical trials. "
05/01/1996 - "In short, the combination of ch14.18 and rhGM-CSF resulted in toxicity similar to that observed with ch14.18 alone without improvement in tumor response."
07/01/2005 - "There was no difference in CDC mediated specific tumor cell lysis among the three different ch14.18 antibody preparations. "
09/01/1999 - "Ch14.18 penetration was limited to approximately 20 cell layers, demonstrating that ch14.18 has limited access to some cells in large tumor nodules. "
09/01/1999 - "with M-21 cells resulted in detectable ch14.18 binding to tumor cells in vivo within 10 hours of antibody administration. "
01/01/1992 - "However, patients receiving greater than 45 mg of ch14.18 had antibody detectable on tumor cells analyzed by fluorescent activated cell sorter. "
12/01/1997 - "These studies have demonstrated the feasibility of concurrent administration of rIL-2 with the mouse/human chimeric ch14.18 mAb. Although the early pilot studies were conducted in patients with bulky disseminated disease, this approach may be more effective in patients with minimal residual disease. "
11/05/1997 - "Our data suggest that a study of ch14.18-IL-2 as an adjuvant treatment in patients with minimal residual disease may be of value."
07/01/2006 - "Dose-limiting toxicities were severe allergic reactions to both ch14.18 and R24 as well as pain related to ch14.18. "
01/01/2015 - "Dexmedetomidine infusion may be an effective and safe pain management adjunct to opioid therapy for the pain of ch14.18 infusion."
04/01/2010 - "We investigated if a point mutation in ch14.18 antibody (hu14.18K332A) to limit complement-dependent cytotoxicity (CDC) would ameliorate the pain behavior, while preserving antibody-dependent cellular cytotoxicity (ADCC). "
01/01/2014 - "Pain, however, can limit immunotherapy with anti-GD2 therapeutic antibodies like ch14.18. "
05/01/2005 - "Consolidation treatment with ch14.18 was tolerable but associated with fever, elevated CRP, rash, cough, and pain as side effects. "
|5.||Neoplasm Metastasis (Metastasis)
07/01/2005 - "Importantly, the ch14.18/CHO preparation was effective in suppression of experimental liver metastasis in this model. "
10/01/2001 - "After therapy, tumor uptake was visualized longer with mIBG (mean 6.3 m) than with MAb. The chimeric antibody ch14.18 is likely to be valuable for follow-up examinations and for assessment of therapy response because of earlier detection of new metastases."
|2.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|5.||Complement System Proteins (Complement)
|7.||Morphine (MS Contin)
|2.||Stem Cell Transplantation
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|4.||Hematopoietic Stem Cell Transplantation